• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利疫苗接种推广、新冠病毒变异株及非药物干预措施需求的建模

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.

作者信息

Giordano Giulia, Colaneri Marta, Di Filippo Alessandro, Blanchini Franco, Bolzern Paolo, De Nicolao Giuseppe, Sacchi Paolo, Colaneri Patrizio, Bruno Raffaele

机构信息

Department of Industrial Engineering, University of Trento, Trento, Italy.

Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

出版信息

Nat Med. 2021 Jun;27(6):993-998. doi: 10.1038/s41591-021-01334-5. Epub 2021 Apr 16.

DOI:10.1038/s41591-021-01334-5
PMID:33864052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8205853/
Abstract

Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model, which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we outline several scenarios: mass vaccination campaigns with different paces, different transmission rates due to new variants and different enforced countermeasures, including the alternation of opening and closure phases. Our results demonstrate that non-pharmaceutical interventions (NPIs) have a higher effect on the epidemic evolution than vaccination alone, advocating for the need to keep NPIs in place during the first phase of the vaccination campaign. Our model predicts that, from April 2021 to January 2022, in a scenario with no vaccine rollout and weak NPIs ([Formula: see text] = 1.27), as many as 298,000 deaths associated with COVID-19 could occur. However, fast vaccination rollouts could reduce mortality to as few as 51,000 deaths. Implementation of restrictive NPIs ([Formula: see text] = 0.9) could reduce COVID-19 deaths to 30,000 without vaccinating the population and to 18,000 with a fast rollout of vaccines. We also show that, if intermittent open-close strategies are adopted, implementing a closing phase first could reduce deaths (from 47,000 to 27,000 with slow vaccine rollout) and healthcare system costs, without substantive aggravation of socioeconomic losses.

摘要

尽管在2019冠状病毒病(COVID-19)患者的临床护理方面取得了进展,但全人群干预对于控制这场大流行仍然至关重要,新出现的高传播性变种加剧了这场大流行。在本研究中,我们将预测严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染传播的SIDARTHE模型与一个新的基于数据的模型相结合,该模型将新病例与伤亡情况及医疗系统成本联系起来。基于意大利的案例研究,我们概述了几种情景:不同推进速度的大规模疫苗接种运动、因新变种导致的不同传播率以及不同的强制应对措施,包括开放和封闭阶段的交替。我们的结果表明,非药物干预(NPIs)对疫情演变的影响比单纯接种疫苗更大,这表明在疫苗接种运动的第一阶段需要继续实施NPIs。我们的模型预测,从2021年4月到2022年1月,在没有疫苗推广且NPIs较弱([公式:见正文] = 1.27)的情景下,与COVID-19相关的死亡人数可能多达29.8万。然而,快速的疫苗推广可将死亡率降至低至5.1万。实施限制性NPIs([公式:见正文] = 0.9)可在不进行人群接种的情况下将COVID-19死亡人数降至3万,在快速推广疫苗的情况下降至1.8万。我们还表明,如果采用间歇性的开放-封闭策略,先实施封闭阶段可减少死亡人数(在疫苗推广缓慢的情况下从4.7万降至2.7万)和医疗系统成本,而不会实质性加剧社会经济损失。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/bf8a7075b442/41591_2021_1334_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/272f31452818/41591_2021_1334_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/7315d412953e/41591_2021_1334_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/f5b91938d9a4/41591_2021_1334_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/960baac3f5b9/41591_2021_1334_Fig4_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/d8db5c9f8fd9/41591_2021_1334_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/32f844154cf8/41591_2021_1334_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/78a119f39378/41591_2021_1334_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/3b2561482254/41591_2021_1334_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/184c56811746/41591_2021_1334_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/ec109b2280d8/41591_2021_1334_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/08f7521b25fd/41591_2021_1334_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/bf8a7075b442/41591_2021_1334_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/272f31452818/41591_2021_1334_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/7315d412953e/41591_2021_1334_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/f5b91938d9a4/41591_2021_1334_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/960baac3f5b9/41591_2021_1334_Fig4_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/d8db5c9f8fd9/41591_2021_1334_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/32f844154cf8/41591_2021_1334_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/78a119f39378/41591_2021_1334_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/3b2561482254/41591_2021_1334_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/184c56811746/41591_2021_1334_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/ec109b2280d8/41591_2021_1334_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/08f7521b25fd/41591_2021_1334_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cd/8205853/bf8a7075b442/41591_2021_1334_Fig12_ESM.jpg

相似文献

1
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.意大利疫苗接种推广、新冠病毒变异株及非药物干预措施需求的建模
Nat Med. 2021 Jun;27(6):993-998. doi: 10.1038/s41591-021-01334-5. Epub 2021 Apr 16.
2
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland.接种疫苗和非药物干预措施对瑞士 SARS-CoV-2 动力学的影响。
Epidemics. 2022 Mar;38:100535. doi: 10.1016/j.epidem.2021.100535. Epub 2021 Dec 14.
3
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.2019冠状病毒病的疫苗接种与非药物干预措施:一项数学建模研究
Lancet Infect Dis. 2021 Jun;21(6):793-802. doi: 10.1016/S1473-3099(21)00143-2. Epub 2021 Mar 18.
4
SARS-CoV-2 transmission in opposition-controlled Northwest Syria: modeling pandemic responses during political conflict.叙利亚反对派控制地区的 2019 年冠状病毒病传播:在政治冲突期间模拟大流行应对措施。
Int J Infect Dis. 2022 Apr;117:103-115. doi: 10.1016/j.ijid.2022.01.062. Epub 2022 Feb 2.
5
Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study.加拿大努纳武特地区非药物干预和疫苗接种对 COVID-19 疫情的影响:加拿大免疫研究网络(CIRN)研究。
BMC Public Health. 2022 May 25;22(1):1042. doi: 10.1186/s12889-022-13432-1.
6
Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.模拟 COVID-19 疫苗接种和非药物干预措施与感染、住院和死亡的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2110782. doi: 10.1001/jamanetworkopen.2021.10782.
7
Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.非药物干预措施、疫苗接种和 SARS-CoV-2 德尔塔变异株在英国:一项数学建模研究。
Lancet. 2021 Nov 13;398(10313):1825-1835. doi: 10.1016/S0140-6736(21)02276-5. Epub 2021 Oct 28.
8
Political determinants of COVID-19 restrictions and vaccine rollouts: The case of regional elections in Italy and Spain.新冠疫情限制措施和疫苗推广的政治决定因素:意大利和西班牙地区选举案例。
Health Policy. 2024 Jul;145:105082. doi: 10.1016/j.healthpol.2024.105082. Epub 2024 May 16.
9
Mathematical modelling of vaccination rollout and NPIs lifting on COVID-19 transmission with VOC: a case study in Toronto, Canada.基于 COVID-19 变异株的疫苗接种推广和非药物干预措施解除对传播影响的数学建模:以加拿大多伦多为例的案例研究。
BMC Public Health. 2022 Jul 15;22(1):1349. doi: 10.1186/s12889-022-13597-9.
10
A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines.一个灵活的、与年龄相关的、具有空间分层的 COVID-19 传播预测模型,考虑了多种病毒变体和疫苗。
PLoS One. 2023 Jan 20;18(1):e0277505. doi: 10.1371/journal.pone.0277505. eCollection 2023.

引用本文的文献

1
Critical Assessment of Large Language Models' (ChatGPT) Performance in Data Extraction for Systematic Reviews: Exploratory Study.大型语言模型(ChatGPT)在系统评价数据提取中的性能批判性评估:探索性研究
JMIR AI. 2025 Sep 11;4:e68097. doi: 10.2196/68097.
2
The Italian public health response during the pandemic emergency: from qualitative data to the "performance index" of care provided by Spoleto Hospital.意大利在大流行紧急情况下的公共卫生应对措施:从定性数据到斯波莱托医院提供的护理“绩效指数”
Front Public Health. 2025 Jun 16;13:1337375. doi: 10.3389/fpubh.2025.1337375. eCollection 2025.
3
Insights from qualitative and bifurcation analysis of COVID-19 vaccination model in Bangladesh.

本文引用的文献

1
Network models to evaluate vaccine strategies towards herd immunity in COVID-19.用于评估 COVID-19 群体免疫疫苗策略的网络模型。
J Theor Biol. 2021 Dec 21;531:110894. doi: 10.1016/j.jtbi.2021.110894. Epub 2021 Sep 9.
2
Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19.模拟新冠病毒变异株和疫苗对新冠疫情传播的影响。
Commun Nonlinear Sci Numer Simul. 2021 Nov;102:105937. doi: 10.1016/j.cnsns.2021.105937. Epub 2021 Jun 24.
3
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
孟加拉国 COVID-19 疫苗接种模型的定性和分岔分析的见解。
PLoS One. 2024 Nov 1;19(11):e0312780. doi: 10.1371/journal.pone.0312780. eCollection 2024.
4
Modelling the impact of vaccination on COVID-19 in African countries.建模评估疫苗接种对非洲国家 COVID-19 的影响。
PLoS Comput Biol. 2024 Oct 23;20(10):e1012456. doi: 10.1371/journal.pcbi.1012456. eCollection 2024 Oct.
5
Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach.评估新冠疫苗接种对疾病传播的动态变化及影响:一种数据驱动的方法。
Infect Dis Model. 2024 Mar 12;9(2):527-556. doi: 10.1016/j.idm.2024.02.010. eCollection 2024 Jun.
6
Revisiting the complex time-varying effect of non-pharmaceutical interventions on COVID-19 transmission in the United States.重新探讨非药物干预措施对美国 COVID-19 传播的复杂时变影响。
Front Public Health. 2024 Feb 21;12:1343950. doi: 10.3389/fpubh.2024.1343950. eCollection 2024.
7
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States.比较美国不同风险组加强针接种预防 COVID-19 重症的频率。
Nat Commun. 2024 Mar 6;15(1):1883. doi: 10.1038/s41467-024-45549-9.
8
Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana.模拟提高疫苗接种覆盖率和采取针对2019年冠状病毒病的非药物干预措施对加纳健康状况的影响。
Pathog Glob Health. 2024 May;118(3):262-276. doi: 10.1080/20477724.2024.2313787. Epub 2024 Feb 6.
9
An Epidemic Model with Infection Age and Vaccination Age Structure.一个具有感染年龄和接种年龄结构的流行病模型。
Infect Dis Rep. 2024 Jan 10;16(1):35-64. doi: 10.3390/idr16010004.
10
Detection of COVID-19 epidemic outbreak using machine learning.利用机器学习检测新冠疫情爆发
Front Public Health. 2023 Dec 18;11:1252357. doi: 10.3389/fpubh.2023.1252357. eCollection 2023.
科维希尔德腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
4
Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.不同新冠疫苗的最佳使用方法:病毒变体与疫苗效力问题
JAMA. 2021 Apr 6;325(13):1251-1252. doi: 10.1001/jama.2021.3465.
5
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.在英格兰,估计 SARS-CoV-2 谱系 B.1.1.7 的传染性和影响。
Science. 2021 Apr 9;372(6538). doi: 10.1126/science.abg3055. Epub 2021 Mar 3.
6
First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.2020 年 12 月 14 日至 2021 年 1 月 13 日,COVID-19 疫苗安全监测第一个月-美国。
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288. doi: 10.15585/mmwr.mm7008e3.
7
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19(阿斯利康)疫苗免疫原性和有效性的影响:四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
8
SARS-CoV-2 variants and ending the COVID-19 pandemic.严重急性呼吸综合征冠状病毒2变体与终结2019冠状病毒病大流行
Lancet. 2021 Mar 13;397(10278):952-954. doi: 10.1016/S0140-6736(21)00370-6. Epub 2021 Feb 11.
9
Understanding variants of SARS-CoV-2.了解严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的变种。
Lancet. 2021 Feb 6;397(10273):462. doi: 10.1016/S0140-6736(21)00298-1.
10
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.预测用于治疗 COVID-19 的抗体所识别的病毒突变逃逸情况。
Science. 2021 Feb 19;371(6531):850-854. doi: 10.1126/science.abf9302. Epub 2021 Jan 25.